866-997-4948(US-Canada Toll Free)

Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Sep 2017

Category :

Pharmaceutical

No. of Pages : 199 Pages

Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Pipeline Review, H2 2017, provides an overview of the Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) pipeline landscape.

Post-Polycythemia Vera Myelofibrosis (PPV-MF) is a myeloproliferative blood cancer in which the bone marrow makes too many red blood cells. It may also result in the overproduction of white blood cells and platelets. Symptoms include heart attack, stroke, deep venous thrombosis, Headaches, lack of concentration and fatigue. The disease may be controlled by chemotherapy, transfusions, transplant and medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 12, 5 and 1 respectively.

Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Overview 6
Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Products under Development by Companies 10
Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Therapeutics Assessment 11
Assessment by Target 11
Assessment by Mechanism of Action 13
Assessment by Route of Administration 15
Assessment by Molecule Type 17
Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Companies Involved in Therapeutics Development 19
AbbVie Inc 19
Celgene Corp 19
CTI BioPharma Corp 20
F. Hoffmann-La Roche Ltd 20
Gilead Sciences Inc 21
Incyte Corp 21
Italfarmaco SpA 22
JW Pharmaceutical Corp 22
MedImmune LLC 23
MEI Pharma Inc 23
Merck & Co Inc 24
Novartis AG 24
NS Pharma Inc 25
Promedior Inc 25
Sun Pharma Advanced Research Company Ltd 26
Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Drug Profiles 27
buparlisib hydrochloride-Drug Profile 27
CWP-291-Drug Profile 33
durvalumab-Drug Profile 35
givinostat-Drug Profile 54
glasdegib-Drug Profile 57
idelalisib-Drug Profile 60
IMG-7289-Drug Profile 68
INCB-50465-Drug Profile 70
itacitinib adipate-Drug Profile 72
LCL-161-Drug Profile 76
navitoclax dihydrochloride-Drug Profile 77
NS-018-Drug Profile 80
pacritinib-Drug Profile 82
pembrolizumab-Drug Profile 96
pomalidomide-Drug Profile 164
pracinostat-Drug Profile 171
PRM-151-Drug Profile 178
sonidegib phosphate-Drug Profile 183
vismodegib-Drug Profile 188
Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Dormant Projects 194
Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Discontinued Products 195
Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Product Development Milestones 196
Featured News & Press Releases 196
Appendix 197
Methodology 197
Coverage 197
Secondary Research 197
Primary Research 197
Expert Panel Validation 197
Contact Us 197
Disclaimer 198

List of Tables
Number of Products under Development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Pipeline by AbbVie Inc, H2 2017
Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Pipeline by Celgene Corp, H2 2017
Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Pipeline by CTI BioPharma Corp, H2 2017
Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Pipeline by Gilead Sciences Inc, H2 2017
Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Pipeline by Incyte Corp, H2 2017
Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Pipeline by Italfarmaco SpA, H2 2017
Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Pipeline by JW Pharmaceutical Corp, H2 2017
Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Pipeline by MedImmune LLC, H2 2017
Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Pipeline by MEI Pharma Inc, H2 2017
Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Pipeline by Merck & Co Inc, H2 2017
Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Pipeline by Novartis AG, H2 2017
Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Pipeline by NS Pharma Inc, H2 2017
Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Pipeline by Promedior Inc, H2 2017
Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017
Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Dormant Projects, H2 2017
Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Discontinued Products, H2 2017

List of Figures
Number of Products under Development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *